LIANBIO

$2.61 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About LIANBIO

Lianbio is a China-based company engaged in the research and development (R&D) and commercialization of innovative drugs. The Company has established production lines for nine candidate products, including Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX13, LYR210, Sisunatovir. The Company's products cover five different treatment areas, including cardiovascular, cancer, ophthalmology, inflammatory diseases and respiratory indications.

Stock Analysis

last close $2.61
1-mo return 8.3%
3-mo return 21.4%
avg daily vol. 231.7T
52-week high 16.37
52-week low 2.1
market cap. $248M
forward pe -
annual div. -
roe -183.1%
ltg forecast 23%
dividend yield -
annual rev. $--
inst own. 79.5%
baraka

Subscribe now for daily local and international financial news

Subscribe